Cyproterone Acetate , >98.0%(HPLC) , 427-51-0

Synonym(s):
6-Chloro-1β,2β-dihydro-17-hydroxy-3′H-cyclopropa(1,2)-pregna-1,4,6-triene-3,20-dione acetate;Cyproterone acetate

CAS NO.：427-51-0

Empirical Formula: C24H29ClO4

Molecular Weight: 416.94

MDL number: MFCD00864671

EINECS: 207-048-3

PRODUCT Properties

• Melting point: 200-201°C
• Boiling point: 528.8°C (rough estimate)
• Density: 1.0677 (rough estimate)
• refractive index: 1.4429 (estimate)
• storage temp.: Sealed in dry,Store in freezer, under -20°C
• solubility: Practically insoluble in water, very soluble in methylene chloride, freely soluble in acetone, soluble in methanol, sparingly soluble in anhydrous ethanol.
• form: Solid
• color: White to Off-White
• λmax: 281nm(MeOH)(lit.)
• Merck: 14,2774
• InChIKey: UWFYSQMTEOIJJG-KIXORDEXNA-N
• SMILES: C[C@@]12C(=CC(=O)[C@@H]3C[C@H]13)C(Cl)=C[C@@]1([H])[C@]3([H])CC[C@@](C(=O)C)(OC(=O)C)[C@@]3(C)CC[C@]21[H] |&1:1,6,8,12,14,18,26,30,r|
• EPA Substance Registry System: 3'H-Cyclopropa[1,2]pregna-1,4,6-triene-3,20-dione, 17-(acetyloxy)-6-chloro-1,2-dihydro-, (1.beta.,2.beta.)- (427-51-0)

Description and Uses

Cyproterone acetate (CPA) is an androgen receptor antagonist. It binds to human androgen receptors (K_i = 14 nM) and inhibits dihydrotestosterone-induced androgen receptor activation in CV-1 cells (IC₅₀ = 26 nM). CPA (30 mg/kg) decreases ventral prostate weight in castrated immature rats. It also suppresses accessory sexual glands and fertility in adult male rats when administered at a dose of 10 mg/kg. CPA (0.3 μM) also induces apoptosis in primary adult female rat hepatocytes. Formulations containing cyproterone acetate have been used in the treatment of androgenization in females.

Cyproterone acetate (CPA) has been shown to exert gestagenic and glucocorticoid effects. Because it inhibits the negative diencephalic pituitary testicular feedback system, it lowers luteinizing hormone (LH) and testosterone production and plasma levels. cyproterone acetate is both an anti-androgen and a progestogen. CPA is used in combined birth control pills, in the treatment of androgen-dependent skin and hair conditions such as acne (Combined with estrogen), seborrhea, excessive hair growth, and scalp hair loss, high androgen levels, in transgender hormone therapy, to treat prostate cancer, to reduce sex drive in sex offenders or men with paraphilias or hypersexuality, to treat early puberty, and for other uses. It is used both at low doses and at higher doses.

Safety

• Symbol(GHS): GHS07,GHS08
• Signal word: Warning
• Hazard statements: H312+H332-H351
• Precautionary statements: P202-P261-P280-P302+P352+P312-P304+P340+P312-P308+P313
• Hazard Codes: Xn,Xi
• Risk Statements: 20/21/22-40-36/37/38
• Safety Statements: 22-36-26
• WGK Germany: 3
• RTECS: GZ2230000
• HS Code: 29372900
• Hazardous Substances Data: 427-51-0(Hazardous Substances Data)